Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple ultrasound spot hidden heart strain in Growth-Restricted pregnancies?

NCT ID NCT06343051

Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This pilot study is testing whether a noninvasive ultrasound device, called USCOM, can measure how well the heart is pumping blood in pregnant people who have just been diagnosed with fetal growth restriction (FGR). FGR means the baby is smaller than expected, and this condition can be linked to heart problems. The study will use the USCOM device during a routine prenatal ultrasound to measure cardiac output and systemic vascular resistance, which are indicators of heart function. The goal is to see if this technology can provide useful information to help monitor these pregnancies more closely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
USCOM device (noninvasive ultrasound to measure blood flow from the heart)
What this could lead to
If successful, this could lead to better monitoring tools for pregnancies affected by fetal growth restriction, potentially improving outcomes.
What could go wrong
This is a small pilot study, so results may not be conclusive. The device's measurements may not reliably predict complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

13 people

The number who actually took part.

Started

Jul 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with newly diagnosed fetal growth restriction at greater than 27 weeks 6 days' gestation will be eligible to enroll in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant patients with a new diagnosis of fetal growth restriction (estimated fetal weight \<10th percentile or abdominal circumference \<10th percentile) in the third trimester (gestational age \>27w6d) Exclusion Criteria: * Multiple gestation * Fetal anomalies * Gestational diabetes or pregestational diabetes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fetal growth restriction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fetal growth restriction USCOM

Contacts and locations

Locations

  • Mount Sinai Hospital

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.